In compliance with current regulations, let us know which audience you belong to:
LM® LLLT is our patented photobiomodulation technology—it works by triggering endogenous heating of both eyelids, stimulating ATP production.
Light Modulation® Low-level Light Therapy can be leveraged employing three different light frequencies—each with its own unique benefits and use cases.
DED/MGD, Chalazion, Stye, Sjögren’s Syndrome, Blepharitis, Ocular Surgery, Ectropion
Demodex, Blepharitis, Rosacea
Post-Invasive Surgery (e.g., Blepharoplasty)
STONECIPHER, Karl, et al. Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. Clinical Ophthalmology, 2019
And consequently, the treatment improved by 10 points or more the patient’s ocular surface disease index—i.e., OSDI Index, in over 70% of cases, with only one treatment.
Recently run thermography studies have shown upper and lower meibomian glands being simultaneously, directly treated at optimal temperature—i.e., 42°C, through LM® LLLT.
Light Modulation® LLLT triggers endogenous heating to both eyelids, stimulating ATP production and removing blockage from meibomian glands preventing proper functioning—and it does so with zero discomfort for the patient.